---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-008621"
form_type: "8-K"
ticker: "IRD"
cik: "0001228627"
company_name: "Opus Genetics, Inc."
filed_at: "2026-03-10T23:59:59+00:00"
generated_at: "2026-05-15T15:31:55.912077+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Opus Genetics reports FY2025 net loss $49.6M; cash $70.1M; PDUFA date Oct 2026

## Summary
- Net loss $49.6M ($0.80/sh) vs $57.5M ($2.15/sh) in 2024; revenue $14.2M from Viatris collab.
- Cash $45.1M at Dec 31, 2025; raised $25M in private placement to $70.1M; runway into H1 2028.
- BEST1 gene therapy: sentinel patient showed 12-letter BCVA gain and 23% CST decrease; three-month data from full cohort expected mid-2026.
- FDA set PDUFA date Oct 17, 2026 for Phentolamine Ophthalmic Solution 0.75% for presbyopia.
- Phase 3 LCA5 trial enrolling; RDEP review submission planned Q1 2026; MERTK funding secured from Abu Dhabi fund.

## SEC filing metadata
- accession: 0001140361-26-008621
- form_type: 8-K
- ticker: IRD
- cik: 0001228627
- company_name: Opus Genetics, Inc.
- filed_at: 2026-03-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1228627/000114036126008621/0001140361-26-008621-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1228627/000114036126008621/ef20067388_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-008621
- JSON: https://secwatch.observer/filing/0001140361-26-008621.json
- Plain text: https://secwatch.observer/filing/0001140361-26-008621.txt

## Key facts
- Earnings Releases
  Opus Genetics, Inc. reported the year ended December 31, 2025 results: revenue $14.2 million.
  - Period: the year ended December 31, 2025
  - Revenue: $14.2 million
  - Result: reported results
  source text: Revenue : License and collaborations revenue totaled $14.2 million for the year ended December 31, 2025, compared to $11.0 million for the same period in 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1228627/000114036126008621/0001140361-26-008621-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.